347 related articles for article (PubMed ID: 34986246)
1. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
Lamoth F; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
[TBL] [Abstract][Full Text] [Related]
2. How urgent is the need for new antifungals?
Stewart AG; Paterson DL
Expert Opin Pharmacother; 2021 Oct; 22(14):1857-1870. PubMed ID: 34231434
[No Abstract] [Full Text] [Related]
3. Emerging Diagnostics and Therapeutics for Invasive Fungal Infections.
Friedman DZP; Schwartz IS
Infect Dis Clin North Am; 2023 Sep; 37(3):593-616. PubMed ID: 37532392
[TBL] [Abstract][Full Text] [Related]
4. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Hoenigl M; Sprute R; Egger M; Arastehfar A; Cornely OA; Krause R; Lass-Flörl C; Prattes J; Spec A; Thompson GR; Wiederhold N; Jenks JD
Drugs; 2021 Oct; 81(15):1703-1729. PubMed ID: 34626339
[TBL] [Abstract][Full Text] [Related]
5. The antifungal pipeline for invasive fungal diseases: what does the future hold?
Neoh CF; Jeong W; Kong DC; Slavin MA
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):577-594. PubMed ID: 37057677
[TBL] [Abstract][Full Text] [Related]
6. New treatment options for critically important WHO fungal priority pathogens.
Kriegl L; Egger M; Boyer J; Hoenigl M; Krause R
Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38461942
[TBL] [Abstract][Full Text] [Related]
7. Novel antifungal agents in clinical trials.
Jacobs SE; Zagaliotis P; Walsh TJ
F1000Res; 2021; 10():507. PubMed ID: 35136573
[TBL] [Abstract][Full Text] [Related]
8. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R
Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026
[TBL] [Abstract][Full Text] [Related]
9. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Invasive Aspergillosis: How It's Going, Where It's Heading.
Boyer J; Feys S; Zsifkovits I; Hoenigl M; Egger M
Mycopathologia; 2023 Oct; 188(5):667-681. PubMed ID: 37100963
[TBL] [Abstract][Full Text] [Related]
11. Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.
Gamaletsou MN; Walsh TJ; Sipsas NV
Turk J Haematol; 2018 Mar; 35(1):1-11. PubMed ID: 29391334
[TBL] [Abstract][Full Text] [Related]
12. Innovative therapies for invasive fungal infections in preclinical and clinical development.
Yu Y; Albrecht K; Groll J; Beilhack A
Expert Opin Investig Drugs; 2020 Sep; 29(9):961-971. PubMed ID: 32662681
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
14. [Invasive fungal infection over the last 30 years].
Silva JT; Ruiz-Camps I; Aguado JM
Rev Iberoam Micol; 2021; 38(2):47-51. PubMed ID: 34294520
[TBL] [Abstract][Full Text] [Related]
15. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective.
Hsu AJ; Hanisch BR; Fisher BT; Huppler AR
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S68-S79. PubMed ID: 38417087
[TBL] [Abstract][Full Text] [Related]
16.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
17. Antifungal Resistance and the Role of New Therapeutic Agents.
Logan A; Wolfe A; Williamson JC
Curr Infect Dis Rep; 2022; 24(9):105-116. PubMed ID: 35812838
[TBL] [Abstract][Full Text] [Related]
18. Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline.
Khalfe Y; Rosen T
J Drugs Dermatol; 2022 May; 21(5):496-501. PubMed ID: 35533026
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
[TBL] [Abstract][Full Text] [Related]
20. Review of the Novel Investigational Antifungal Olorofim.
Wiederhold NP
J Fungi (Basel); 2020 Jul; 6(3):. PubMed ID: 32751765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
